新型老年健康综合干预技术研发与规范体系构建

注册号:

Registration number:

ChiCTR2500104351 

最近更新日期:

Date of Last Refreshed on:

2025-06-16 10:59:29 

注册时间:

Date of Registration:

2025-06-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

新型老年健康综合干预技术研发与规范体系构建

Public title:

Research of new comprehensive intervention technologies and development of a regulatory system on health in older adults

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型老年健康综合干预技术研发与规范体系构建

Scientific title:

Research of new comprehensive intervention technologies and development of a regulatory system on health in older adults

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

潘一鸣 

研究负责人:

马丽娜 

Applicant:

Yiming Pan 

Study leader:

Lina Ma 

申请注册联系人电话:

Applicant telephone:

+86 135 8166 9691

研究负责人电话:

Study leader's
telephone:

+86 176 0010 7787

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

panym33@sina.com

研究负责人电子邮件:

Study leader's E-mail:

malina0883@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市长椿街45号

研究负责人通讯地址:

北京市长椿街45号

Applicant address:

No. 45, Changchun Street, Beijing

Study leader's address:

No. 45, Changchun Street, Beijing

申请注册联系人邮政编码:

Applicant postcode:

100053

研究负责人邮政编码:

Study leader's postcode:

100053

申请人所在单位:

首都医科大学宣武医院

Applicant's institution:

Xuanwu Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学宣武医院

Affiliation of the Leader:

Xuanwu Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临研审[2023] 218号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学宣武医院伦理委员会

Name of the ethic committee:

Ethics Committee of Xuanwu Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-11-29 00:00:00

伦理委员会联系人:

王威

Contact Name of the ethic committee:

Wei Wang

伦理委员会联系地址:

北京市长椿街45号

Contact Address of the ethic committee:

No. 45, Changchun Street, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8319 9270

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学宣武医院

Primary sponsor:

Xuanwu Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区长椿街45号

Primary sponsor's address:

No. 45, Changchun Street, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院

具体地址:

北京市西城区长椿街45号

Institution
hospital:

Xuanwu Hospital, Capital Medical University

Address:

No. 45, Changchun Street, Beijing

国家:

中国

省(直辖市):

湖南

市(区县):

长沙

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

中南大学湘雅医院

具体地址:

湖南省长沙市开福区湘雅路87号

Institution
hospital:

Xiangya Hospital, Central South University

Address:

No. 87, Xiangya Road, Kaifu District, Changsha City, Hunan Province

国家:

中国

省(直辖市):

湖南

市(区县):

长沙

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

中南大学湘雅二医院

具体地址:

湖南省长沙市人民路139号

Institution
hospital:

The Second Xiangya Hospital of Central South University

Address:

No. 139 Renmin Road, Changsha City, Hunan Province

经费或物资来源:

国家重点研发计划课题(项目编号:2023YFC3603404)

Source(s) of funding:

National Key R&D Program of China (Project No.: 2023YFC3603404)

研究疾病:

老年综合征  

Target disease:

Geriatric syndrome

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.主要目的:研发老年健康干预新措施。 2.次要目的:制定老年健康管理策略,形成临床干预共识,构建老年健康规范体系。  

Objectives of Study:

1. Main objective: to develop new measures for geriatric health interventions. 2. Secondary objectives: to develop geriatric health management strategies, form a consensus on clinical intervention, and construct a standardized system for geriatric health.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.不能配合完成所有评估或样本采集:如有瘫痪、痴呆或精神疾病者; 2.患有自身免疫病、血液系统疾病或恶性肿瘤; 3.有严重的肝功能或肾功能不全; 4.有严重的感染性疾病; 5.正在应用激素或免疫抑制剂治疗; 6.不愿参与或不签署知情同意书。

Exclusion criteria:

1. Unable to cooperate with all assessments or sample collection: such as paralysis, dementia or mental illness; 2. Suffering from autoimmune diseases, hematologic diseases or malignant tumors; 3. Have severe hepatic or renal insufficiency; 4. Have a serious infectious disease; 5. Ongoing treatment with hormones or immunosuppressants; 6. Unwilling to participate or not to sign the informed consent form.

研究实施时间:

Study execute time:

From 2023-12-01 00:00:00 To 2026-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-23 00:00:00 To 2026-11-30 00:00:00

干预措施:

Interventions:

组别:

试验组1

样本量:

50

Group:

Experimental group 1

Sample size:

干预措施:

多模式运动干预:包括有氧训练(舞蹈、太极拳等)、抗阻训练(持物卧推、曲臂支撑、弓箭步、弹力带练习等)、平衡训练(足跟行走、足尖行走、S 形行走等)和柔韧性训练(肩部环绕、上肢伸展、小腿拉伸等)。

干预措施代码:

Intervention:

Multimodal exercise intervention: including aerobic training (dance, Tai Chi, etc.), resistance training (bench press with objects, bent arm support, lunge, elastic band exercises, etc.), balance training (heel walking, toe walking, S-shaped walking, etc.) and flexibility training (shoulder circle, upper limb stretching, calf stretching, etc.).

Intervention code:

组别:

对照组1

样本量:

50

Group:

Control group 1

Sample size:

干预措施:

常规健康管理:自由运动,并按照循证医学和临床实践指南的原则接受疾病相关的药物和非药物治疗,同时接受运动相关健康知识宣传教育。

干预措施代码:

Intervention:

Routine health management: free exercise, and receive disease-related drug and non-drug treatment according to the principles of evidence-based medicine and clinical practice guidelines, and receive education on exercise-related health knowledge.

Intervention code:

组别:

试验组 2

样本量:

50

Group:

Experimental group 2

Sample size:

干预措施:

个性化营养指导:包括设定营养目标、制定营养处方、辅助膳食强化、优化营养摄入方式、吞咽功能康复、口腔状况评估与管理。

干预措施代码:

Intervention:

Personalized nutrition guidance: including setting nutrition goals, formulating nutrition prescriptions, assisting in dietary fortification, optimizing nutrition intake, swallowing function rehabilitation, and oral condition assessment and management.

Intervention code:

组别:

对照组2

样本量:

50

Group:

Control group 2

Sample size:

干预措施:

常规健康管理:所有受试者自由饮食,并将按照循证医学和临床实践指南的原则接受疾病相关的药物和非药物治疗,同时接受营养相关健康知识宣传教育。

干预措施代码:

Intervention:

Routine health management: All subjects will be free to eat and drink, and will receive disease-related drug and non-drug treatment in accordance with the principles of evidence-based medicine and clinical practice guidelines, as well as nutrition-related health knowledge education.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院 

单位级别:

三甲 

Institution
hospital:

Xuanwu Hospital, Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

中南大学湘雅医院 

单位级别:

三甲 

Institution
hospital:

Xiangya Hospital, Central South University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

中南大学湘雅二医院 

单位级别:

三甲 

Institution
hospital:

The Second Xiangya Hospital of Central South University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

日常生活活动能力评估量表评分

指标类型:

主要指标

Outcome:

Activities of Daily Living Ability Assessment Scale score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

跌倒

指标类型:

主要指标

Outcome:

Falls

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

死亡

指标类型:

主要指标

Outcome:

Mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简易体能状况量表

指标类型:

次要指标

Outcome:

Simple Physical Performance Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

微型营养评估简表

指标类型:

次要指标

Outcome:

Mini Nutritional Assessment Short Form

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

内在能力

指标类型:

次要指标

Outcome:

Intrinsic capacity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

衰弱表型

指标类型:

次要指标

Outcome:

Frailty phenotype

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

慢性病数目

指标类型:

次要指标

Outcome:

Number of chronic diseases

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

用药数量

指标类型:

次要指标

Outcome:

Number of medications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

衰老相关生物标志物

指标类型:

次要指标

Outcome:

Aging-related biomarkers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计师采用SPSS软件产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

Statisticians use SPSS software to generate random sequences.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF;EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF;EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-06-16 10:59:24